Metabolic Complications of Androgen Deprivation Therapy for Prostate Cancer
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
PURPOSE: Androgen deprivation therapy has a variety of well recognized adverse effects including vasomotor flushing, loss of libido, fatigue, gynecomastia, anemia and osteoporosis. This review focuses on the more recently described metabolic complications of androgen deprivation therapy including obesity, insulin resistance and lipid alterations as well as the association of androgen deprivation therapy with diabetes and cardiovascular disease. MATERIALS AND METHODS: We reviewed the medical literature using the PubMed(R) search terms prostate cancer, androgen deprivation therapy, gonadotropin-releasing hormone agonists, obesity, insulin resistance, lipids, diabetes, cardiovascular disease and myocardial infarction. We provide a focused review and our perspective on the relevant literature. RESULTS: Androgen deprivation therapy decreases lean mass and increases fat mass. It also decreases insulin sensitivity while increasing low density lipoprotein cholesterol, high density lipoprotein cholesterol and triglycerides. Consistent with these adverse metabolic effects, androgen deprivation therapy may be associated with a greater incidence of diabetes and cardiovascular disease. Some of these androgen deprivation therapy related metabolic changes (obesity, insulin resistance and increased triglycerides) overlap with features of the metabolic syndrome. However, in contrast to the metabolic syndrome, androgen deprivation therapy increases subcutaneous fat and high density lipoprotein cholesterol. CONCLUSIONS: Androgen deprivation therapy increases obesity, decreases insulin sensitivity and adversely alters lipid profiles. It may be associated with a greater incidence of diabetes and cardiovascular disease. The benefits of androgen deprivation therapy should be weighed against these and other potential harms. Little is known about the optimal strategy to mitigate the adverse metabolic effects of androgen deprivation therapy. Thus, we recommend an emphasis on existing strategies for screening and treatment that have been documented to reduce the risk of diabetes and cardiovascular disease in the general population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
The Metabolic Syndrome: Time for a Critical Appraisal
Kahn, R., Buse, J., Ferrannini, E., & Stern, M. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2289 · Cited by 2,378
Obesity and Diabetes in the Developing World — A Growing Challenge
Hossain, P., Kawar, B., & El Nahas, M. (2007) · New England Journal of Medicine · doi:10.1056/nejmp068177 · Cited by 2,200
Hyperinsulinemia as an independent risk factor for ischemic heart disease
Després, J.-P., Lamarche, B., Mauriège, P., Cantin, B., Dagenais, G. R., Moorjani, S., & Lupien, P.-J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604113341504 · Cited by 1,699
Cited by
Cancer treatment and survivorship statistics, 2019
Miller, K. D., Nogueira, L., Mariotto, A. B., Rowland, J. H., Yabroff, K. R., Alfano, C. M., Jemal, A., Kramer, J. L., & Siegel, R. L. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21565 · Cited by 4,226
Cancer treatment and survivorship statistics, 2014
DeSantis, C. E., Lin, C. C., Mariotto, A. B., Siegel, R. L., Stein, K. D., Kramer, J. L., Alteri, R., Robbins, A. S., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21235 · Cited by 2,779
Cornford, P., Bellmunt, J., Bolla, M., Briers, E., De Santis, M., Gross, T., Henry, A. M., Joniau, S., Lam, T. B., Mason, M. D., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.08.002 · Cited by 1,438
Heidenreich, A., Bastian, P. J., Bellmunt, J., Bolla, M., Joniau, S., van der Kwast, T., Mason, M., Matveev, V., Wiegel, T., Zattoni, F., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.11.002 · Cited by 1,341
Cornford, P., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Cumberbatch, M. G., De Santis, M., Fanti, S., Fossati, N., Gandaglia, G., Gillessen, S., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.09.046 · Cited by 1,079
Vigneri, P., Frasca, F., Sciacca, L., Pandini, G., & Vigneri, R. (2009) · Endocrine Related Cancer · doi:10.1677/erc-09-0087 · Cited by 1,009
Radiotherapy and Short-Term Androgen Deprivation for Localized Prostate Cancer
Jones, C. U., Hunt, D., McGowan, D. G., Amin, M. B., Chetner, M. P., Bruner, D. W., Leibenhaut, M. H., Husain, S. M., Rotman, M., Souhami, L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012348 · Cited by 696
Mottet, N., Bellmunt, J., Bolla, M., Joniau, S., Mason, M., Matveev, V., Schmid, H.-P., Van der Kwast, T., Wiegel, T., Zattoni, F., et al. (2011) · European Urology · doi:10.1016/j.eururo.2011.01.025 · Cited by 493
Gilchrist, S. C., Barac, A., Ades, P. A., Alfano, C. M., Franklin, B. A., Jones, L. W., La Gerche, A., Ligibel, J. A., Lopez, G., Madan, K., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000679 · Cited by 472
American Cancer Society prostate cancer survivorship care guidelines
Skolarus, T. A., Wolf, A. M. D., Erb, N. L., Brooks, D. D., Rivers, B. M., Underwood, W., Salner, A. L., Zelefsky, M. J., Aragon‐Ching, J. B., Slovin, S. F., et al. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21234 · Cited by 398
Lalonde, E., Ishkanian, A. S., Sykes, J., Fraser, M., Ross-Adams, H., Erho, N., Dunning, M. J., Halim, S., Lamb, A. D., Moon, N. C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71021-6 · Cited by 342
Long-Term and Latent Side Effects of Specific Cancer Types
Gegechkori, N., Haines, L., & Lin, J. J. (2017) · Medical Clinics of North America · doi:10.1016/j.mcna.2017.06.003 · Cited by 286
Contemporary Role of Androgen Deprivation Therapy for Prostate Cancer
Pagliarulo, V., Bracarda, S., Eisenberger, M. A., Mottet, N., Schröder, F. H., Sternberg, C. N., & Studer, U. E. (2012) · European Urology · doi:10.1016/j.eururo.2011.08.026 · Cited by 266
O'Farrell, S., Garmo, H., Holmberg, L., Adolfsson, J., Stattin, P., & Van Hemelrijck, M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.1792 · Cited by 265
Onset of effects of testosterone treatment and time span until maximum effects are achieved
Saad, F., Aversa, A., Isidori, A. M., Zafalon, L., Zitzmann, M., & Gooren, L. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0221 · Cited by 232
Obesity and late-onset hypogonadism
Corona, G., Vignozzi, L., Sforza, A., Mannucci, E., & Maggi, M. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.06.031 · Cited by 154
Male Obesity-related Secondary Hypogonadism – Pathophysiology, Clinical Implications and Management
Fernandez, C. J., Department of Endocrinology & Metabolism, P. H., Chacko, E. C., Department of Endocrinology, J. G. H., Pappachan, J. M., & Department of Endocrinology & Metabolism, L. T. H. N. F. T. (2019) · European Endocrinology · doi:10.17925/ee.2019.15.2.83 · Cited by 145
Castration influences intestinal microflora and induces abdominal obesity in high-fat diet-fed mice
Harada, N., Hanaoka, R., Horiuchi, H., Kitakaze, T., Mitani, T., Inui, H., & Yamaji, R. (2016) · Scientific Reports · doi:10.1038/srep23001 · Cited by 110
Storer, T. W., Miciek, R., & Travison, T. G. (2012) · Asian Journal of Andrology · doi:10.1038/aja.2011.104 · Cited by 70
Male hypogonadism causes obesity associated with impairment of hepatic gluconeogenesis in mice
Aoki, A., Fujitani, K., Takagi, K., Kimura, T., Nagase, H., & Nakanishi, T. (2016) · Biological & Pharmaceutical Bulletin · doi:10.1248/bpb.b15-00942 · Cited by 18
Metadata
- Authors
- Saylor, P. J., & Smith, M. R.
- Venue
- Journal of Urology
- Published
- 2009-05
- Volume
- 181
- Issue
- 5
- Pages
- 1998-2008
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2128543455
- Cited by
- 349
- References
- 69
- FWCI
- 20.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.